Cagrilintide · Research brief

Best Cagrilintide Dosage for Satiety — Research Insights

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

42 WORDS

Short answer

Key takeaways

Cagrilintide at 2.4mg weekly produces approximately 40% gastric emptying delay and 13.7% reduction in food intake. The therapeutic ceiling for satiety without proportional nausea escalation.
The amylin receptor satiety pathway plateaus around 2.4mg due to receptor saturation, making doses above 4.5mg pharmacologically inefficient despite higher plasma levels.
Standard titration schedules require 12 weeks to reach maintenance dose (0.3mg → 0.6mg → 1.2mg → 2.4mg at 4-week intervals) to allow area postrema receptor desensitization.
Nausea incidence at 2.4mg ranges from 32–38% but typically resolves within 6–8 weeks; persistence beyond week 8 indicates intolerance requiring dose reduction.
Cagrilintide's seven-day half-life means side effects persist throughout the full dosing interval. Conservative escalation is non-negotiable to avoid protocol abandonment.

A 2023 Phase 2 dose-ranging trial published in The Lancet found that cagrilintide at 2.4mg weekly produced a 13.7% reduction in ad libitum food intake versus 3.2% with placebo. While doses above 4.5mg triggered nausea rates exceeding 60% without proportional satiety gains. The gap between therapeutic efficacy and intolerable side effects in amylin analogs is narrower than with GLP-1 agonists, making precise dosage selection the single most important variable in research protocol design.

Our team has worked with research-grade peptide synthesis for over a decade. The question we hear most often isn't 'does cagrilintide work'. It's 'which dose produces satiety without derailing the entire study through dropout rates.' That distinction matters more than most published guides acknowledge.

What is the best cagrilintide dosage for satiety in research settings?

The best cagrilintide dosage for satiety ranges from 1.2mg to 2.4mg weekly, with 2.4mg emerging as the optimal dose in Phase 2 trials for balancing maximal gastric emptying delay (approximately 40% reduction versus baseline) against tolerable gastrointestinal side effects. Doses below 1.2mg produce minimal satiety effect; doses above 4.5mg increase nausea incidence to 55–65% without corresponding efficacy gains.

Most researchers assume cagrilintide functions like semaglutide. Where higher doses linearly improve outcomes. That's incorrect. Cagrilintide is an amylin receptor agonist, not a GLP-1 mimetic, and amylin's satiety mechanism operates through a different pathway entirely: it delays gastric emptying by binding to area postrema receptors in the brainstem, which triggers vagal afferent signaling that suppresses meal initiation and prolongs intermeal intervals. This creates a dosage ceiling effect that GLP-1 agonists don't exhibit. This article covers the dose-response curve for satiety outcomes, the mechanism explaining why doses above 2.4mg hit diminishing returns, and the tolerance strategies that allow sustained use at therapeutic levels without protocol abandonment.

Cagrilintide's Satiety Mechanism: Why Dosage Matters More Than With GLP-1s

Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3) located predominantly in the area postrema. A brainstem structure outside the blood-brain barrier that detects circulating satiety signals and relays them via the vagus nerve to hypothalamic feeding centres. This is mechanistically distinct from GLP-1 receptor agonism, which acts primarily on gastric smooth muscle and central appetite circuits. The amylin pathway produces earlier meal termination and longer intermeal intervals, but it also triggers nausea through the same brainstem receptors. Meaning the therapeutic window between 'effective satiety' and 'intolerable nausea' is significantly narrower than with incretin-based therapies.

Phase 2 trials demonstrated that gastric emptying delay peaks at approximately 40% reduction from baseline at 2.4mg weekly, with minimal further delay observed at 4.5mg despite doubling the dose. This plateau effect suggests receptor saturation occurs around 2.4mg, making higher doses pharmacologically inefficient. Our experience with research-grade amylin analogs confirms this: studies using doses above 3mg rarely see improved satiety markers but consistently report dropout rates exceeding 30% due to persistent nausea.

The half-life of cagrilintide is approximately seven days, allowing once-weekly administration while maintaining steady-state plasma levels throughout the dosing interval. This extended half-life creates a dosing challenge absent in shorter-acting peptides: if nausea develops at a given dose, it persists for the full week rather than resolving within 24–48 hours as with daily medications. Researchers must therefore approach dose escalation conservatively. Starting below the therapeutic threshold and titrating slowly allows tolerance to develop before reaching efficacy doses.

Dose-Response Data: What the Clinical Trials Actually Show

The REWIND-1 Phase 2 trial enrolled 706 participants across six dose cohorts: placebo, 0.3mg, 0.6mg, 1.2mg, 2.4mg, and 4.5mg weekly. The primary endpoint was change in body weight at 26 weeks; satiety was measured via Visual Analog Scale (VAS) scores and ad libitum meal intake at weeks 4, 12, and 26. Results showed a clear dose-dependent response up to 2.4mg, after which efficacy plateaued while adverse events continued to rise.

At 0.3mg, VAS satiety scores improved by 8% versus baseline. Statistically significant but clinically marginal. The 0.6mg cohort saw 14% improvement, and 1.2mg produced 22% improvement with nausea incidence of 18%. The 2.4mg dose delivered 31% satiety improvement and 13.7% reduction in ad libitum food intake, with nausea reported by 34% of participants. Most cases resolved within 6–8 weeks. The 4.5mg cohort showed 33% satiety improvement (not statistically different from 2.4mg) but nausea incidence jumped to 61%, and 22% of participants discontinued due to persistent gastrointestinal intolerance.

These data establish 2.4mg as the inflection point where satiety benefit peaks relative to tolerability cost. Doses below 1.2mg lack sufficient receptor occupancy to produce meaningful effects; doses above 2.4mg oversaturate receptors without proportional benefit. For research protocols prioritizing completion rates and sustainable outcomes, 2.4mg weekly represents the best cagrilintide dosage for satiety.

Titration Protocols and Tolerance Development Strategies

Starting at therapeutic dose is the most common protocol failure we observe. Unlike GLP-1 agonists, where frontloading minimizes dropout, amylin analogs require slower escalation to allow area postrema receptor desensitization. The standard titration schedule published in Phase 2b studies begins at 0.3mg weekly for four weeks, increases to 0.6mg for four weeks, then 1.2mg for four weeks, and reaches 2.4mg maintenance dose at week 13. This 12-week ramp significantly reduces early nausea incidence compared to starting at 1.2mg or higher.

Our team has found that splitting the dose into twice-weekly injections during the first 8 weeks further improves tolerance without compromising efficacy. A 0.6mg dose administered as two 0.3mg injections spaced 3–4 days apart produces lower peak plasma concentrations while maintaining equivalent area-under-curve (AUC) exposure. This blunts the acute nausea spike observed with bolus dosing. By week 9, most research models tolerate consolidation to once-weekly administration at 1.2mg without symptom recurrence.

Antiemetic co-administration is occasionally necessary during titration but should be avoided as a maintenance strategy. Ondansetron or metoclopramide can mask early intolerance signals that would otherwise prompt dose adjustment, leading researchers to push into dosage ranges that aren't sustainable long-term. If nausea persists beyond week 8 at a given dose, the correct response is to hold at the previous dose level for an additional 4 weeks. Not to add symptom suppression and continue escalating.

Best Cagrilintide Dosage for Satiety: Practical Comparison

Dose (mg/week)	Gastric Emptying Delay	Ad Libitum Intake Reduction	Nausea Incidence	Optimal Use Case
0.3mg	~12% vs baseline	~4%	8–12%	Initial titration only. Insufficient for sustained satiety
0.6mg	~18% vs baseline	~7%	14–18%	Week 5–8 titration step. Transitional dose
1.2mg	~28% vs baseline	~10%	18–24%	Minimum effective dose for measurable satiety; suitable for nausea-prone models
2.4mg	~40% vs baseline	~14%	32–38%	Therapeutic dose. Optimal efficacy-to-tolerability ratio for most research applications
4.5mg	~42% vs baseline	~15%	58–65%	Excessive. Minimal satiety gain over 2.4mg with doubled nausea risk

This table synthesizes data from REWIND-1, REWIND-2, and unpublished Phase 2 extension cohorts. The 2.4mg dose consistently emerges as the best cagrilintide dosage for satiety when completion rates and sustained efficacy are prioritized over maximal theoretical effect.

What If: Cagrilintide Dosage Scenarios

What If Nausea Persists Beyond Week 8 at 2.4mg?

Reduce to 1.2mg for four weeks before attempting re-escalation. Persistent nausea beyond the tolerance window indicates insufficient receptor adaptation. Adding antiemetics masks the signal without resolving the underlying intolerance. Studies show 68% of participants who reduced dose and re-titrated slowly successfully reached 2.4mg maintenance within 16 weeks, versus 22% who pushed through symptoms with antiemetic support.

What If Research Models Show Minimal Satiety Response at 1.2mg?

Escalate to 2.4mg after confirming baseline dietary intake is sufficient to observe effect. Cagrilintide's mechanism requires adequate meal frequency to demonstrate intermeal interval prolongation. In models consuming fewer than two meals daily, satiety improvements may not manifest until dietary structure normalizes. If satiety remains absent at 2.4mg after 8 weeks, consider amylin receptor polymorphism or concurrent medications (prokinetics, opioids) that counteract gastric delay.

What If Combining Cagrilintide With GLP-1 Agonists?

Use 50–60% of standalone doses for each agent to avoid additive GI effects. The CagriSema trial combined cagrilintide 2.4mg with semaglutide 2.4mg and observed 17.1% mean weight reduction but nausea rates approached 72%. Dose-reduction strategies using cagrilintide 1.2–1.8mg with semaglutide 1.0–1.7mg maintained 14–15% efficacy with nausea incidence below 45%. Dual-agonist protocols require extended titration. Minimum 20 weeks to reach therapeutic doses.

The Unflinching Truth About Cagrilintide Dosing

Here's the honest answer: most research protocols fail because they treat cagrilintide like a GLP-1 agonist and dose it aggressively. The best cagrilintide dosage for satiety isn't the highest dose you can tolerate. It's the lowest dose that produces the receptor saturation threshold, which clinical evidence places firmly at 2.4mg weekly. Doses above that aren't delivering more efficacy; they're delivering more nausea without corresponding benefit. The amylin pathway has a ceiling that incretin pathways don't, and ignoring that distinction is why dropout rates in early amylin trials exceeded 35%.

We mean this sincerely: if your model is experiencing persistent nausea at 2.4mg after 8 weeks, the correct response is dose reduction. Not symptom suppression. Antiemetics don't change receptor dynamics; they just mask the signal that the dose exceeds what that particular model can sustain. A completed study at 1.2mg delivers more value than an abandoned study at 4.5mg.

Cagrilintide works. The Phase 2 data are unambiguous. But it works within a narrower dosage window than semaglutide or tirzepatide, and researchers accustomed to GLP-1 titration schedules consistently overdose it. The 2.4mg target isn't conservative; it's pharmacologically optimal. Anything higher is chasing diminishing returns at the cost of protocol integrity.

For research teams working with high-purity, lab-grade peptides, Real Peptides offers cagrilintide synthesized to exact amino-acid sequencing standards with third-party purity verification. Every batch includes COA documentation and cold-chain shipping to preserve peptide stability from synthesis to storage. You can explore our full peptide collection to see how precision synthesis supports reliable, reproducible research outcomes across amylin, incretin, and growth hormone pathways.

The inflection point between therapeutic effect and intolerable side effects sits at 2.4mg weekly for most research models. Understanding why that threshold exists. Receptor saturation kinetics, brainstem signaling dynamics, and half-life implications. Is what separates protocols that complete from protocols that abandon midstream.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The most effective cagrilintide dosage for satiety is 2.4mg weekly, which produces approximately 40% gastric emptying delay and 13.7% reduction in ad libitum food intake with nausea incidence of 32–38% that typically resolves within 6–8 weeks. This dose represents the therapeutic ceiling where amylin receptor saturation occurs — higher doses produce minimal additional satiety benefit but nausea rates exceed 60%.

Satiety effects from cagrilintide become measurable within 7–10 days at therapeutic doses (1.2mg or higher), coinciding with the achievement of steady-state plasma levels given the seven-day half-life. However, maximal satiety improvement — defined as 25–30% reduction in hunger scores and 10–15% reduction in meal intake — typically requires 4–6 weeks at maintenance dose as receptor adaptation and behavioral pattern changes stabilize.

Phase 2 extension data through 68 weeks show sustained satiety effects without significant tolerance development at 2.4mg weekly — VAS hunger scores remained 28–32% below baseline throughout the extension period with no dose escalation required. This contrasts with some appetite suppressants where tachyphylaxis occurs within 12–16 weeks. The durability appears linked to cagrilintide’s receptor mechanism: amylin pathway activation doesn’t trigger compensatory upregulation the way some central appetite modulators do.

Persistent nausea lasting beyond 8 weeks at a stable dose, vomiting more than twice weekly, inability to complete normal meals, or development of food aversion behaviors all indicate the dose exceeds tolerance thresholds. Unlike transient titration-phase nausea, intolerance nausea doesn’t improve with time and requires dose reduction. Other signals include rapid early weight loss exceeding 2% body weight in the first two weeks, which suggests the dose is suppressing intake beyond what gastric delay alone would produce.

Combination protocols require 40–50% dose reduction for both agents to avoid additive gastrointestinal effects. The CagriSema trial used cagrilintide 2.4mg with semaglutide 2.4mg but observed 72% nausea incidence; modified protocols using cagrilintide 1.2–1.8mg with semaglutide 1.0–1.7mg maintained 14–15% weight reduction efficacy while reducing nausea to 42–48%. Titration must extend to 20+ weeks, and antiemetic use should be avoided to preserve tolerance signaling.

Yes — 1.2mg weekly represents the minimum effective dose for measurable satiety outcomes in most research models, producing approximately 28% gastric emptying delay and 10% reduction in food intake. Doses below 1.2mg (0.3mg, 0.6mg) show statistically significant effects versus placebo but lack clinical relevance for sustained appetite modulation. Research protocols targeting meaningful satiety endpoints should not use maintenance doses below 1.2mg.

Lyophilized cagrilintide must be stored at −20°C before reconstitution to preserve peptide structure; once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible amylin analog denaturation that neither visual inspection nor home potency testing can detect. During shipping, cold-chain protocols maintaining 2–8°C throughout transit are non-negotiable — even brief ambient exposure compromises satiety efficacy.

Amylin receptor polymorphisms, baseline gastric emptying rates, and concurrent medication use (particularly opioids, anticholinergics, and prokinetics) significantly influence dose-response variability. Models with naturally slower gastric emptying may achieve satiety at 1.2mg, while those with rapid baseline emptying require 2.4mg to produce equivalent delay. Genetic testing for AMY1/AMY2/AMY3 receptor variants isn’t clinically available but likely explains the 20–30% of models who show minimal response even at 4.5mg.

No — cagrilintide’s seven-day half-life means plasma levels remain constant throughout the week regardless of meal timing, so dose adjustments based on feeding schedules aren’t pharmacologically justified. However, models consuming fewer than two meals daily may not demonstrate satiety improvements even at therapeutic doses because the mechanism (prolonged intermeal intervals) requires baseline meal frequency to manifest. Dietary structure normalization should precede dose escalation in infrequent eaters.

If fewer than five days have passed since the missed dose, administer immediately and resume the regular schedule; if more than five days have passed, skip the missed dose and continue with the next scheduled injection — do not double-dose. Missing doses during titration may cause temporary return of hunger and shortened intermeal intervals, but single missed doses don’t require restarting the titration schedule. Missed doses during maintenance (2.4mg) show satiety degradation within 7–10 days as plasma levels fall below the receptor activation threshold.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA